Literature DB >> 17696804

Biochemical mechanisms of nephrotoxicity: application for metabolomics.

Claus U Niemann1, Natalie J Serkova.   

Abstract

This review describes biochemical pathways of nephrotoxicity and the application of metabolic biomarkers as they relate to nephrotoxicity. Specific and sensitive biomarkers constitute the missing link in the continuum of exposure to toxins and susceptibility, disease development and possible therapeutic intervention. Important requirements for biomarker development are a detailed understanding of biochemical pathways involved in nephrotoxicity, minimal invasiveness and capacity to screen large at-risk populations. Lastly, possible biomarker candidates should be organ specific and equally applicable in preclinical drug testing as well as in clinical care of patients. This review discusses four major metabolic pathways associated with disturbed renal homeostasis: i) direct metabolic evidence of abnormal excretion of endogenous metabolites; ii) disturbances in kidney osmolarity and renal osmolyte homeostasis; iii) impaired energy state followed by dysregulation of glucose, fatty acid and ketone body metabolism; and iv) oxidative stress in renal tissues. Each of these pathways can be monitored by specific surrogate markers in urine and blood using modern metabolomics technologies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696804     DOI: 10.1517/17425225.3.4.527

Source DB:  PubMed          Journal:  Expert Opin Drug Metab Toxicol        ISSN: 1742-5255            Impact factor:   4.481


  14 in total

1.  A high-performance liquid chromatography-tandem mass spectrometry-based targeted metabolomics kidney dysfunction marker panel in human urine.

Authors:  Jacek Klepacki; Jost Klawitter; Jelena Klawitter; Joshua M Thurman; Uwe Christians
Journal:  Clin Chim Acta       Date:  2015-04-11       Impact factor: 3.786

Review 2.  The emerging field of quantitative blood metabolomics for biomarker discovery in critical illnesses.

Authors:  Natalie J Serkova; Theodore J Standiford; Kathleen A Stringer
Journal:  Am J Respir Crit Care Med       Date:  2011-06-16       Impact factor: 21.405

3.  Screening and validation for plasma biomarkers of nephrotoxicity based on metabolomics in male rats.

Authors:  Yubo Li; Haoyue Deng; Liang Ju; Xiuxiu Zhang; Zhenzhu Zhang; Zhen Yang; Lei Wang; Zhiguo Hou; Yanjun Zhang
Journal:  Toxicol Res (Camb)       Date:  2015-11-05       Impact factor: 3.524

Review 4.  Metabolomics in the study of kidney diseases.

Authors:  Robert H Weiss; Kyoungmi Kim
Journal:  Nat Rev Nephrol       Date:  2011-10-25       Impact factor: 28.314

5.  NMR spectroscopy and electron microscopy identification of metabolic and ultrastructural changes to the kidney following ischemia-reperfusion injury.

Authors:  Tafadzwa Chihanga; Qing Ma; Jenna D Nicholson; Hannah N Ruby; Richard E Edelmann; Prasad Devarajan; Michael A Kennedy
Journal:  Am J Physiol Renal Physiol       Date:  2017-10-04

Review 6.  Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites.

Authors:  Jia Liu; Lawrence Litt; Mark R Segal; Mark J S Kelly; Jeffrey G Pelton; Myungwon Kim
Journal:  Int J Mol Sci       Date:  2011-09-28       Impact factor: 5.923

7.  Biomarkers of acute kidney injury.

Authors:  Jeffrey C Sirota; Jelena Klawitter; Charles L Edelstein
Journal:  J Toxicol       Date:  2011-10-29

8.  Meso scale discovery and luminex comparative analysis of calbindin D28K.

Authors:  Samer Sourial; Maritha Marcusson-Ståhl; Karin Cederbrant
Journal:  J Biomed Biotechnol       Date:  2009-10-11

Review 9.  Emerging biomarkers and metabolomics for assessing toxic nephropathy and acute kidney injury (AKI) in neonatology.

Authors:  M Mussap; A Noto; V Fanos; J N Van Den Anker
Journal:  Biomed Res Int       Date:  2014-06-11       Impact factor: 3.411

10.  Kidney Tissue Targeted Metabolic Profiling of Unilateral Ureteral Obstruction Rats by NMR.

Authors:  Zhenyu Li; Aiping Li; Jining Gao; Hong Li; Xuemei Qin
Journal:  Front Pharmacol       Date:  2016-09-15       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.